| Unaudited Reconciliation of Net Income to Non-IFRS EBITDA | ||||||||||||
| Three Months Ended | ||||||||||||
| (in millions USD) | March 31, 2024 | December 31, 2023 | March 31, 2023 | |||||||||
| Net income for the period | $ | 134 | $ | 278 | $ | 254 | ||||||
| Depreciation and amortization | 392 | $ | 402 | 343 | ||||||||
| Finance expense | 37 | $ | 35 | 31 | ||||||||
| Finance income | (47 | ) | $ | (43 | ) | (32 | ) | |||||
| Income tax expense (benefit) | 21 | $ | 21 | 23 | ||||||||
| Share-based compensation | 40 | $ | 50 | 31 | ||||||||
| Restructuring charges | — | $ | 30 | 5 | ||||||||
| Non-IFRS EBITDA (1) (2) | $ | 577 | $ | 773 | $ | 655 | ||||||
| Non-IFRS EBITDA margin (1) (2) | 37.2 | % | 41.7 | % | 35.6 | % | ||||||
<
